Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2010 1
2011 2
2014 1
2017 1
2019 3
2020 2
2021 3
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Amyotrophic lateral sclerosis type 3"
Page 1
Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease.
Ng L, Khan F, Young CA, Galea M. Ng L, et al. Cochrane Database Syst Rev. 2017 Jan 10;1(1):CD011776. doi: 10.1002/14651858.CD011776.pub2. Cochrane Database Syst Rev. 2017. PMID: 28072907 Free PMC article. Review.
BACKGROUND: Motor neuron disease (MND), which is also known as amyotrophic lateral sclerosis (ALS), causes a wide range of symptoms but the evidence base for the effectiveness of the symptomatic treatment therapies is limited. ...Treatment for sialorrhoeaA si …
BACKGROUND: Motor neuron disease (MND), which is also known as amyotrophic lateral sclerosis (ALS), causes a wide range …
Burden of Neurological Disorders Across the US From 1990-2017: A Global Burden of Disease Study.
GBD 2017 US Neurological Disorders Collaborators; Feigin VL, Vos T, Alahdab F, Amit AML, Bärnighausen TW, Beghi E, Beheshti M, Chavan PP, Criqui MH, Desai R, Dhamminda Dharmaratne S, Dorsey ER, Wilder Eagan A, Elgendy IY, Filip I, Giampaoli S, Giussani G, Hafezi-Nejad N, Hole MK, Ikeda T, Owens Johnson C, Kalani R, Khatab K, Khubchandani J, Kim D, Koroshetz WJ, Krishnamoorthy V, Krishnamurthi RV, Liu X, Lo WD, Logroscino G, Mensah GA, Miller TR, Mohammed S, Mokdad AH, Moradi-Lakeh M, Morrison SD, Shivamurthy VKN, Naghavi M, Nichols E, Norrving B, Odell CM, Pupillo E, Radfar A, Roth GA, Shafieesabet A, Sheikh A, Sheikhbahaei S, Shin JI, Singh JA, Steiner TJ, Stovner LJ, Wallin MT, Weiss J, Wu C, Zunt JR, Adelson JD, Murray CJL. GBD 2017 US Neurological Disorders Collaborators, et al. JAMA Neurol. 2021 Feb 1;78(2):165-176. doi: 10.1001/jamaneurol.2020.4152. JAMA Neurol. 2021. PMID: 33136137 Free PMC article.
MAIN OUTCOME AND MEASURE: Absolute numbers in detail by age and sex and age-standardized rates (with 95% uncertainty intervals) were calculated. RESULTS: The 3 most burdensome neurological disorders in the US in terms of absolute number of DALYs were stroke (3.58 [9 …
MAIN OUTCOME AND MEASURE: Absolute numbers in detail by age and sex and age-standardized rates (with 95% uncertainty intervals) were calcula …
Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.
James E, Ellis C, Brassington R, Sathasivam S, Young CA. James E, et al. Cochrane Database Syst Rev. 2022 May 20;5(5):CD006981. doi: 10.1002/14651858.CD006981.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593746 Free PMC article. Review.
BACKGROUND: Motor neuron disease (MND), also known as amyotrophic lateral sclerosis (ALS), is a progressive neurodegenerative condition that may cause dysphagia, as well as limb weakness, dysarthria, emotional lability, and respiratory failure. ...The trial p …
BACKGROUND: Motor neuron disease (MND), also known as amyotrophic lateral sclerosis (ALS), is a progressive neurodegene …
Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis.
Byrne S, Walsh C, Lynch C, Bede P, Elamin M, Kenna K, McLaughlin R, Hardiman O. Byrne S, et al. J Neurol Neurosurg Psychiatry. 2011 Jun;82(6):623-7. doi: 10.1136/jnnp.2010.224501. Epub 2010 Nov 3. J Neurol Neurosurg Psychiatry. 2011. PMID: 21047878 Review.
BACKGROUND: The population rate of familial amyotrophic lateral sclerosis (FALS) is frequently reported as 10%. ...METHOD: A Medline literature review identified all original articles reporting a rate of FALS. Studies were grouped according to the type …
BACKGROUND: The population rate of familial amyotrophic lateral sclerosis (FALS) is frequently reported as 10%. ...METH …
Association between Galectin Levels and Neurodegenerative Diseases: Systematic Review and Meta-Analysis.
Ramos-Martínez E, Ramos-Martínez I, Sánchez-Betancourt I, Ramos-Martínez JC, Peña-Corona SI, Valencia J, Saucedo R, Almeida-Aguirre EKP, Cerbón M. Ramos-Martínez E, et al. Biomolecules. 2022 Jul 31;12(8):1062. doi: 10.3390/biom12081062. Biomolecules. 2022. PMID: 36008956 Free PMC article. Review.
Patients with neurodegenerative diseases present a higher level of galectin expression compared to healthy individuals (MDS = 0.70, 95% CI 0.28-1.13, p = 0.001). In the subgroup analysis by galectin type, a higher galectin-3 expression is observed in patients with n …
Patients with neurodegenerative diseases present a higher level of galectin expression compared to healthy individuals (MDS = 0.70, 95% CI 0 …
A systematic review of neuropsychiatric and cognitive assessments used in clinical trials for amyotrophic lateral sclerosis.
Beswick E, Park E, Wong C, Mehta AR, Dakin R, Chandran S, Newton J, Carson A, Abrahams S, Pal S. Beswick E, et al. J Neurol. 2021 Dec;268(12):4510-4521. doi: 10.1007/s00415-020-10203-z. Epub 2020 Sep 10. J Neurol. 2021. PMID: 32910255 Free PMC article. Review.
BACKGROUND: Up to 50% of people with amyotrophic lateral sclerosis (ALS) experience cognitive dysfunction, whilst depression and anxiety are reported in up to 44% and 33%, respectively. ...METHODS: We reviewed the past 25 years of clinical trials of investiga …
BACKGROUND: Up to 50% of people with amyotrophic lateral sclerosis (ALS) experience cognitive dysfunction, whilst depre …
Cervical spondylotic amyotrophy: a systematic review.
Luo W, Li Y, Xu Q, Gu R, Zhao J. Luo W, et al. Eur Spine J. 2019 Oct;28(10):2293-2301. doi: 10.1007/s00586-019-05990-7. Epub 2019 Apr 29. Eur Spine J. 2019. PMID: 31037421
METHODS: A comprehensive search of PubMed, EMBASE, Cochrane library and Web of Science databases was conducted, from their inception to April 3, 2018. RESULTS: Clinically, CSA is classified into three types: a proximal-type (involving the scapular muscles, deltoid a …
METHODS: A comprehensive search of PubMed, EMBASE, Cochrane library and Web of Science databases was conducted, from their inception to Apri …
Neutral theory: applicability and neutrality of clinical study endpoints where a disease-specific instrument is available.
Jandhyala R. Jandhyala R. BMC Med Res Methodol. 2023 May 20;23(1):121. doi: 10.1186/s12874-023-01947-z. BMC Med Res Methodol. 2023. PMID: 37210484 Free PMC article.
RESULTS: Around half the clinical studies for half the rare diseases with one disease-specific disease severity score (palmoplantar psoriasis, achalasia, systemic lupus erythematosus, systemic sclerosis and Fournier's gangrene) met the threshold for an acceptable match to …
RESULTS: Around half the clinical studies for half the rare diseases with one disease-specific disease severity score (palmoplantar psoriasi …
A systematic review of digital technology to evaluate motor function and disease progression in motor neuron disease.
Beswick E, Fawcett T, Hassan Z, Forbes D, Dakin R, Newton J, Abrahams S, Carson A, Chandran S, Perry D, Pal S. Beswick E, et al. J Neurol. 2022 Dec;269(12):6254-6268. doi: 10.1007/s00415-022-11312-7. Epub 2022 Aug 9. J Neurol. 2022. PMID: 35945397 Free PMC article. Review.
Amyotrophic lateral sclerosis (ALS) is the most common subtype of motor neuron disease (MND). ...Twenty studies, involving 1275 (median 28 and ranging 6-584) pwMND, were included. Sensor type included accelerometers (n = 9), activity monitors (n = 4), …
Amyotrophic lateral sclerosis (ALS) is the most common subtype of motor neuron disease (MND). ...Twenty studies, involv …
Promoting excellence in end-of-life care in ALS.
Mitsumoto H, Bromberg M, Johnston W, Tandan R, Byock I, Lyon M, Miller RG, Appel SH, Benditt J, Bernat JL, Borasio GD, Carver AC, Clawson L, Del Bene ML, Kasarskis EJ, LeGrand SB, Mandler R, McCarthy J, Munsat T, Newman D, Sufit RL, Versenyi A. Mitsumoto H, et al. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005 Sep;6(3):145-54. doi: 10.1080/14660820510028647. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005. PMID: 16183556 Review.
The type and quality of end-of-life care varies greatly in ALS; the time to initiate end-of-life care is not defined, and decision making is hampered by logistical and financial barriers. ...The ALS Peer Workgroup reviewed the literature and 1) identified the current state …
The type and quality of end-of-life care varies greatly in ALS; the time to initiate end-of-life care is not defined, and decision ma …
16 results